Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies

A study found that outpatient observation cut hospital stays dramatically, with no adverse safety events reported. It also freed up inpatient beds and cut healthcare costs.

By
January 9, 2026
4 min

Fox Chase Cancer Center

Original Source(s)

Fox Chase Cancer Center

Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies

by
January 9, 2026

Related Content

Blood Cancer Journal (Nature Portfolio)

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar
April 28, 2026

Bone Marrow Transplantation

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda
May 27, 2026

Frontiers In Immunology

Epstein-Barr virus associated diseases: Immune alterations and targeted approaches

by Shijia Cao, Jie Xiong, Jiayi Zhao, Wei-Li Zhao
May 8, 2026